Andrea Necchi

Research interests

Publications

• ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.03.001

• Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2309863

• Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

  European Urology · 2023 · https://doi.org/10.1016/j.eururo.2023.03.029

• European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update

  European Urology · 2023 · https://doi.org/10.1016/j.eururo.2023.02.027

• Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03292

• Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.11.012

• Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00094-2

• Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03296

• Penile cancer

  Nature Reviews Disease Primers · 2021 · https://doi.org/10.1038/s41572-021-00246-5

• Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

  JCO Precision Oncology · 2020 · https://doi.org/10.1200/po.19.00345

• Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz127

• EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz296

• Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

  European Urology · 2019 · https://doi.org/10.1016/j.eururo.2019.10.026

• Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1817323

• EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

  European Urology · 2019 · https://doi.org/10.1016/j.eururo.2019.09.035

• Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

  Journal of Clinical Oncology · 2018 · 10.1200/jco.18.01148

• ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy217

• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1613683

• Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx518

• Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30065-7

• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)00561-4

• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32455-2

• Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

  Cancer · 2015 · https://doi.org/10.1002/cncr.29387

• EAU Guidelines on Penile Cancer: 2014 Update

  European Urology · 2014 · https://doi.org/10.1016/j.eururo.2014.10.017

• Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds579

• Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.32.6678

Current projects

No projects listed.